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expectancy, with reported 5-year survival ranging between
6% and 29% worldwide.1,5
Modern techniques of infrainguinal bypass grafting
(IBG) for limb salvage have resulted in ever-improving
outcomes for patients with critical limb ischemia.
However, the subset of patients with critical limb ischemia
and dialysis-dependent ESRD continues to represent one
of the more difficult vascular surgical challenges. A recent
review of published reports addressing this subject sum-
marized the adverse outcomes as follows: 2-year survival
of 49% (range, 32%-62%), perioperative mortality rate of
9% (range, 0%-27%), early graft thrombosis rate of 14%,
and a greater than 14% amputation rate with a functioning
graft.6 A previously reported series from our institution
highlighted the risks and inferior outcomes associated with
IBG in this cohort.7
At our institution we have seen a significant growth in
the proportion of patients with ESRD among those
requiring IBG over the last decade. Whereas dialysis
patients comprised just 2% of IBG cases between 1978 and
1992, this fraction rose to 14% between 1993 and 1997.8
Our growing exposure to this population led us to reex-
amine the outcomes of a contemporary series.
METHODS
A retrospective review was conducted of patients with
dialysis-dependent ESRD who had undergone IBG with
End-stage renal disease (ESRD), defined as a lack of
native renal function that requires renal replacement ther-
apy (hemodialysis, peritoneal dialysis [PD], or renal trans-
plantation) is undergoing a dramatic increase in prevalence
that is international in scope. The number of patients with
ESRD in the United States in 1998 was 300,000.1 This
number is expected to double by 2010,2 representing a
growth rate of 7% per year.3 This increase primarily resides
in the subgroup of ESRD resulting from type 2 diabetes
mellitus (DM), reflecting both the increasing prevalence
of type 2 DM and improved medical treatment of its other
end-organ complications. With ongoing improvements in
the treatment of hypertension and coronary artery disease
(CAD), more diabetic patients are having ESRD as a late
complication.4 The population of patients with type 2 dia-
betes and ESRD continues to exhibit a limited life
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Objective: This study was undertaken to examine recent trends in the outcomes of patients with end-stage renal disease
(ESRD) undergoing infrainguinal bypass grafting (IBG) with autogenous vein.
Methods: A retrospective analysis of all IBGs performed on patients with ESRD at a single tertiary care institution dur-
ing the interval 1993 to 1999 was undertaken. The comparison groups consisted of concurrent series of patients with
elevated creatinine (creatinine level > 1.2 mg/dL) and patients with normal renal function undergoing IBG. Procedural
variables, angiographic runoff scores, and extent of tissue necrosis at presentation were correlated with outcome.
Categoric parameters were compared with χ2 analysis; rates were computed with life-table analysis.
Results: Of an overall cohort of 622 IBGs performed during this interval, 78 IBGs (12.5%) were performed on 60
patients with ESRD, with a perioperative mortality rate of 1.3% that was comparable to controls. All reconstructions
in the ESRD cohort were for limb salvage indications. Four-year survival, primary, assisted primary, and secondary
patency rates for the ESRD group were 51% ± 9%, 60% ± 11%, 86% ± 5%, and 86% ± 5%, respectively; these were not
statistically different from the control groups. Limb salvage in the ESRD group was 77% ± 6% at 4 years and was sig-
nificantly less then either the elevated creatinine (92% ± 4%; P < .02) or the normal renal function group (90% ± 2%:
P < .02). Of 16 amputations in the ESRD group, nine were performed in limbs with patent grafts. The only absolute
predictor of limb loss despite a patent graft was the presence of a heel ulcer more than 4 cm in diameter. Age, runoff
score of the International Society for Cardiovascular Surgery/Society for Vascular Surgery, isolated tibial bypass graft,
and location of distal anastomosis were not predictive of hemodynamic failure. 
Conclusions: Patients with ESRD constitute an increasing proportion of patients undergoing IBG in a tertiary care set-
ting. Four-year survival, perioperative mortality, and graft patency rates are similar to patients with normal renal func-
tion and support an aggressive approach to this population. Major limb amputation despite a patent graft remains a
problem of unique frequency in patients with ESRD. Adequate predictors of hemodynamic failure of IBG in this group
do not exist, although a heel ulcer more than 4 cm may indicate an unsalvageable foot. (J Vasc Surg 2001;33:1171-8.)
autogenous vein at Brigham and Women’s Hospital between
January 1, 1993, and June 30, 1999. This included 60
patients and 78 separate limbs. Patients with functioning
renal transplants were excluded because of their unique
physiology and pharmacology. The control group consisted
of all patients undergoing autogenous vein IBG at our insti-
tution during the same interval and was subdivided into two
cohorts: those with chronically elevated serum creatinine
(EC) who were not undergoing dialysis (mean creatinine
level > 1.2 mg/dL) and those with normal renal function
(NL) (creatinine level ≤ 1.2 mg/dL). The cutoff creatinine
level of 1.2 mg/dL used to discriminate the control groups
was selected on the basis of the upper limit of the normal
range reported from our institution’s clinical laboratory. 
Data were retrieved from a UNIX-based computer-
ized registry (Sun Microsystems, Mountain View, Calif) 
in which demographics, risk factors, procedure variables,
and follow-up information have been prospectively
entered for all vascular surgery patients since 1975. All
office and hospital charts for the ESRD cohort were
reviewed to verify the data in the UNIX system. The 
primary author reviewed the lower extremity arteriograms
(available for 69 of the 78 limbs) of the ESRD group, 
and runoff scores were calculated as per the Ad Hoc
Committee on Reporting Standards, Society for Vascular
Surgery/International Society for Cardiovascular Surgery.9
Data for the control groups were retrieved from the
UNIX-based system; their charts and arteriograms were
not individually reviewed. 
All revascularizations were performed entirely with
autogenous vein conduit. Composite vein grafts are defined
as those in which two or more pieces of autogenous vein
were anastomosed together. The surgical team included an
attending surgeon and a vascular fellow or senior resident;
loupe magnification, standard surgical techniques, and
completion arteriography were used. The specifics of con-
duit preparation have been previously described in detail
by our group.10,11
Routine follow-up consisted of postoperative visits at
1 month and then 3-month intervals until 1 year, then at
yearly intervals. Duplex scanning of the graft was the pri-
mary method of detecting occult graft lesions. Focal
increase in graft velocity (ratio > 3.5:1) and decreased
graft velocity (< 45 cm/s) were considered significant and
were followed by arteriography and revision when appro-
priate. Patients were considered lost to follow-up if their
whereabouts were not known for 18 months.
Minor amputations are defined as those resulting in a
functional foot. Limb salvage is defined as freedom from
major amputation. Primary, assisted primary, and sec-
ondary patency are defined as suggested by the Ad Hoc
Committee on Reporting Standards, Society for Vascular
Surgery/International Society for Cardiovascular
Surgery.9 Survival, graft patency, and limb salvage rates
were calculated by the life-table method. SEs were calcu-
lated by the Greenwood method.12 Categoric variables
were compared with χ2 analysis. A P value less than .05
was considered to represent statistical significance.
RESULTS
A total of 60 patients with ESRD underwent 78 auto-
genous IBGs between January 1, 1993, and June 30,
1999. In all but three of these patients the origin of renal
failure was presumed to be DM (1 poststreptococcal
glomerulonephritis, 1 congenital nephritis, and 1
nephrosclerosis). Of the 57 patients with diabetes, 47
were insulin dependent. Four of the 60 patients were
undergoing PD, with the remainder undergoing
hemodialysis. Follow-up was considered complete in 82%
of patients for a mean of 16 months (range, 0-63 months).
The control groups consisted of 481 patients with NL
who underwent 581 autogenous IBG reconstructions and
37 patients with EC who underwent 41 autogenous IBG
reconstructions during the same interval. 
Demographics and risk factors. Reflecting the dis-
tinct pathophysiology of their vascular disease, the patients
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Table I. Demographics and risk factor profile of patients
undergoing autogenous vein IBG, 1993-1999.
ESRD EC NL
No. (patients/limbs) 60/78 37/41 481/581
Male:female (%) 46:54 61:39 55:45
Age (y)(mean/median) 63/66* 67/70 69/70
DM (%) 83* 76 44
Smoking (%) 8*† 24 37
CAD (%) 64* 50 50
Prior CABG (%) 26 21 21
Stroke (%) 12 17 12
CHF (%) 22* 17 9
*P < .05, ESRD vs NL.
†P < .05, ESRD vs EC.
CABG, Coronary artery bypass grafting; CAD, coronary artery disease;
CHF, congestive heart failure; DM, diabetes mellitus; EC, elevated creati-
nine; ESRD, end-stage renal disease; NL, normal renal function.
Table II. Selected procedural variables for autogenous
IBGs, 1993-1999
(% of cases) ESRD EC NL
Limb salvage indication 100*† 90 77
Redo bypass graft 6 24 22
Inflow sites
Common femoral artery 41*† 61 63
Superior femoral artery 36*† 15 20
Popliteal artery 23† 24 13
Outflow sites
Popliteal artery 10*† 27 37
Tibial/pedal artery 90*† 73 63
Conduit type
In situ GSV 18† 17 33
Nonreversed GSV 51*† 34 36
Composite vein 9* 17 14
*P < .05, ESRD vs EC.
†P < .05, ESRD vs NL.
with ESRD were significantly younger (mean, 63 vs 69
years), more likely to be diabetic (83% vs 44%), had a
lower exposure to tobacco (8% vs 37%), and a higher inci-
dence of CAD (64% vs 50%) and congestive heart failure
(CHF) (22% vs 9%) than the NL group (Table I). 
Procedural variables. All revascularizations in the
ESRD group were performed for limb salvage indications
(rest pain [15%], ulceration [54%] or gangrene [31%]). By
comparison, preexisting tissue necrosis was present in 48%
of NL and 68% of the EC controls. Disabling claudication
was the indication for surgery in 10% of the EC patients
and 23% of the NL group. A larger percentage of recon-
structions in the ESRD group (94%) was primary bypass
graft, as compared with the control group in which 22% of
procedures were secondary (re-do) bypass grafts (Table II). 
Distal inflow sites were more often used in the ESRD
patients. The superficial femoral artery (36% ESRD vs 15%
EC, 20% NL, P < .05) and popliteal artery (23% ESRD vs
13% NL) were more frequently used for graft origin.
Distal anastomosis to the tibial or pedal level comprised
90% of ESRD reconstructions with the anterior tibial
(27%), dorsalis pedis (24%), and peroneal (21%) arteries
most commonly used. In comparison, 73% of EC (P <
.05) and 63% of NL (P < .05) IBGs were performed to the
tibial/pedal outflow level. Thus, the popliteal artery was
much less frequently used (10% vs 27% EC, 37% NL; P <
.05 ) as a distal anastomotic site in the ESRD cohort. 
Nonreversed greater saphenous vein (GSV) was the
most common type of conduit used in the ESRD group
(51%) in comparison with the EC (34%) and NL (36%)
patients (P < .05). Use of the in situ GSV configuration
was significantly more prevalent in the NL cohort (33% vs
JOURNAL OF VASCULAR SURGERY
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18% ESRD vs 9%, P < .05) than in the ESRD group. Arm
(4%) and composite vein (9%) grafts were infrequently
used in ESRD reconstructions.
Perioperative events. The perioperative (30-day)
mortality rate was statistically similar at 1.3% for the ESRD
patients, 0% for the EC cohort, and 2.3% for the NL
group. In general the individual complication major mor-
bidity rates among the groups (Table III) were likewise
comparable. The ESRD and NL groups had a 3% periop-
erative myocardial infarction rate. Patients with ESRD
experienced a 1% rate of postoperative stroke, 3% early
graft occlusion, 3% early amputation, and 4% wound infec-
tion rate. 
Patient survival, graft patency, and limb salvage.
The 4-year cumulative survival for the 60 patients with
ESRD was 51% ± 9%. Patient survival was not significantly
different between the ESRD and control groups; however,
the 34% 4-year survival among EC patients was significantly
less than that observed in the NL group (63%, P < .01).
Reconstructions in the ESRD group demonstrated 4-year
patency rates of 60% ± 11% (primary), 86% ± 5% (assisted
primary), and 86% ± 5% (secondary). Graft patency results
were similar among all groups (Table IV, Figs 1-4). Four-
year data are reported as the SE for the patency rate, and
survival exceeded 10% in the ESRD cohort at 5 years.
Limb salvage in the ESRD group was 77% ± 6%, sig-
nificantly lower than the other groups and lower than the
secondary patency rate for the grafts in this group. This fact
is explained by the nine major amputations performed
despite functioning IBG in the ESRD group (Table V).
Seven other major amputations were performed in patients
with ESRD after graft failure. The total number of patients
Fig 1. Cumulative survival for patients undergoing IBG 1993-1999. EC, Elevated creatinine; ESRD, end-stage renal disease; NL, nor-
mal renal function.
with ESRD evaluated for limb salvage during this period is
unknown; however, nine primary amputations were per-
formed in patients with ESRD during the study interval. 
In patients with ESRD with preoperative gangrene or
ulceration who went on to successful limb salvage after
IBG, the average number of adjunctive foot operations was
two (range, 0-6). Nine patients with tissue loss involving
the heel went on to successful limb salvage after IBG. Seven
had small ulcers or heel gangrene less than 4 cm and two
had heel fissures. However, all four patients who presented
with wet gangrene or soft eschars of the heel more than 4
cm went on to amputation despite a patent bypass graft. 
Angiographic runoff scores were not predictive of
graft patency or limb salvage in the ESRD cohort. The
ESRD group had a mean runoff score of 6.0 /(median
6.5) for those patients who did not undergo amputation.
The respective mean and median runoff scores for the
group who underwent amputation with an open graft and
with a failed graft were 6.2/5.5 and 8.0/8.0. These values
were not statistically different.
DISCUSSION
The prevalence of ESRD among patients undergoing
IBG at our institution has increased significantly over the
last decade. The hypothesis of this investigation was that
surgical outcomes in this challenging group were improv-
ing compared with our own historical experience. The cur-
rent results demonstrate that perioperative mortality,
surgical morbidity, and 4-year cumulative graft patency and
patient survival for patients with ESRD are not significantly
different from those observed in the overall population
undergoing lower extremity revascularization at our insti-
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Fig 2. Life-table plot of primary patency for autogenous IBG 1993-1999. EC, Elevated creatinine; ESRD, end-stage renal disease; NL,
normal renal function.
Table III. Adverse 30-day perioperative events
(%) ESRD EC NL
Mortality (30 d) 1 0 2
Morbidity
MI 3 0 3
CHF 0 2 1
CVA 1 0 1
Early graft occlusion 3 7 6
Early amputation 3 2 1
Wound infection 4 5 3
Overall morbidity 13*† 29 22
*P < .05, ESRD vs EC.
†P < .05, ESRD vs NL.
CHF, Congestive heart failure; CVA, cerebrovascular accident (stroke);
EC, elevated creatinine; ESRD, end-stage renal disease; MI, myocardial
infarction; NL, normal renal function.
Table IV. Four-year cumulative outcomes (mean ± SE)
% ESRD EC NL
Survival 51 ± 9 34 ± 9* 63 ± 3
Primary patency 60 ± 11 57 ± 10 64 ± 3
Assisted primary patency 86 ± 5 71 ± 9 77 ± 2
Secondary patency 86 ± 5 73 ± 9 78 ± 2
Limb salvage 77 ± 6†‡ 92 ± 4 92 ± 4
*P < .01, EC vs NL.
†P < .05, ESRD vs EC.
‡P < .05, ESRD vs NL.
tution. However, consistent with numerous other reports,
limb salvage is reduced, and the problem of limb loss,
despite a patent graft, occurs with increased frequency in
patients with ESRD. The only preoperative predictor of
hemodynamic failure that we identified was the presence of
a heel ulcer greater than 4 cm in maximal diameter.
The operative mortality rate and 2-year survival for
patients with ESRD undergoing infrainguinal reconstruc-
tion are reported to range from 0% to 27% (mean, 9%) and
32% to 62% (mean, 49%), respectively, in contemporary
series.6 We observed a perioperative mortality rate of 1.3%,
representing a dramatic improvement over the 11% figure
previously reported from our own institution for a historic
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(1977-1992) cohort including both chronic renal insuffi-
ciency and patients with ESRD.7 The 2- and 4-year sur-
vival in the current ESRD group (65% and 51%) is
consistent with the best previously published results.13
Reported survival for the overall US population of patients
with ESRD (ie, without peripheral vascular surgical inter-
vention) at 1-, 2- and 5-years is 75%, 57%, and 30%,
respectively.1 We do not have long-term survival data for
the entire ESRD population that receives tertiary care at
our institution, so it remains unclear if our referral popu-
lation is unique in any way. We postulate that the reduced
morbidity and mortality reflect improved management of
the end-organ manifestations of diabetes, particularly car-
Fig 3. Life-table plot of cumulative secondary patency for autogenous IBG 1993-1999. EC, Elevated creatinine; ESRD, end-stage renal
disease; NL, normal renal function.
Table V. Patients with ESRD who underwent major amputation despite open IBG
Diabetes/ SVS/ISCVS Days until
Indication dialysis type Proximal/distal runoff score Conduit amputation
Pt 1 > 4 cm heel IDDM/PD SFA-AT 8.0 Composite 55 d/AKA
Pt 2 > 4 cm heel IDDM/HD CFA-DP 5.5 NR-GSV 32 d/BKA
Pt 3 Failed TMA IDDM/HD Pop-AT 6.0 R-GSV 14 d/BKA
Pt 4 Forefoot gangrene IDDM/HD CFA-PT NA NR-GSV 16 d/BKA
Pt 5 Great toe dry gangrene IDDM/HD CFA-PT 6.0 IS-GSV 57 d/BKA
Pt 6 > 4 cm heel IDDM/HD CFA-AT 4.5 NR-GSV 660 d/BKA
Pt 7 Ulcer great toe IDDM/HD CFA-AT 5.5 NR-GSV 303 d/AKA
Pt 8 > 4 cm heel IDDM/HD CFA-AT 6.5 NR-GSV 110 d/BKA
Pt 9 Great toe wet gangrene IDDM/HD CFA-PT NA NR-GSV 274 d/BKA
AKA, Above-knee amputation; AT, anterior tibial artery; BKA, below-knee amputation; CFA, common femoral artery; DP, dorsalis pedis; GSV, greater
saphenous vein; HD, hemodialysis; IBG, infrainguinal bypass grafting; IDDM, insulin-dependent diabetes mellitus; IS, in situ; NA, not applicable; NR, non-
reversed; PD, peritoneal dialysis; Pop, popliteal; PT, posterior tibial artery; R, reversed; SFA, superficial femoral artery; SVS/ISCVS, Society for Vascular
Surgery/International Society for Vascular Surgery; TMA, transmetatarsal amputation of foot.
diac disease. The increased 4-year mortality observed in
the group with EC as compared with patients having NL
was not expected and requires further investigation. 
Our preoperative evaluation and perioperative medical
and anesthetic management for IBG has been outlined
elsewhere14; we have not used a specific or unique proto-
col to the patient with ESRD. Preoperative medical and
cardiac evaluation is obtained in all patients, and provoca-
tive cardiac testing is performed selectively on the basis of
a functional, clinical assessment. Dialysis management and
glycemic control are aggressively addressed within the
multidisciplinary team. Unless there are specific con-
traindications, patients are given aspirin and β-adrenergic
blocking agents perioperatively.
Inferior graft patency rates reported from a number of
older series, including our own, raised the question of
whether patients with ESRD were a unique population in
terms of vein graft biology. The primary patency of 60% at
4 years that we report from the current group is markedly
superior to that which we previously reported (22% at 2
years) for a much smaller series of dialysis patients.7 Direct
comparison with the control groups in this report should
not be overinterpreted because the groups are quite dis-
tinct in terms of anatomy, severity of ischemia, and the
proportion of secondary reconstructions. Nevertheless,
the results demonstrate that graft function in the ESRD
cohort appears similar to concurrent controls with mild or
no renal impairment. 
In this series, the 4-year limb salvage rate of 77% ± 9%
in the ESRD group is encouraging, although still lower
than the cumulative graft patency rate. Of the nine
patients with failed grafts, seven went on to major limb
amputation. An additional nine limbs were lost despite
patent grafts, representing 56% of the amputations in this
group. A recently published review of this subject revealed
that historically, 46% of amputations have been performed
in the presence of open grafts in patients with ESRD; con-
versely, 14% of patients with ESRD undergoing IBG will
require major amputation despite open bypass grafts.6 Our
results are remarkably similar in that 13% of patients with
functioning grafts went on to lose their foot.
In an attempt to focus on the factors that lead to fail-
ure despite a patent graft, we evaluated all of the standard
variables including angiographic runoff scores. Age,
tobacco use, type of conduit used, and use of an isolated
anterior tibial target vessel were not significantly different
in the subgroup of patients who experienced hemody-
namic failure of the graft. Several predictors of hemody-
namic failure have been identified in the literature
including preoperative infection, poor functional status
ischemic ulceration greater than 2 cm, tobacco abuse, heel
necrosis greater than 4 cm, forefoot gangrene,15-19 preop-
erative toe pressures less than 20 mm Hg, and a pedal
angiographic resistance score of more than 2.5 (3.0 repre-
senting no named pedal arteries).6 Of note, all four
patients with extensive heel gangrene who underwent
amputation had bypass grafts to their forefoot circulation.
However, most of the other patients with heel lesions who
were completely healed had nondirect flow bypass grafts,
including five to the anterior tibial artery, one to an iso-
lated tibial artery, two to the peroneal artery, and one to
the below-knee popliteal artery. Previous studies have
shown that nondirect flow bypass grafts in patients with-
out ESRD will heal tissue loss.20 Free flaps were not used
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Fig 4. Cumulative limb salvage for patients undergoing autogenous IBG 1993-1999. EC, Elevated creatinine; ESRD, end-stage renal
disease; NL, normal renal function.
in any patients because the experience at our institution
has been unfavorable in the ESRD population. However,
others have reported acceptable results with free tissue
transfer in carefully selected patients with ESRD.21 A
more recent approach to difficult wounds is the vacuum-
assisted closure system, though we have limited experience
in the ESRD population to date.22
This retrospective study cannot adequately assess pre-
dictors of poor outcome and did not measure postopera-
tive functional outcomes in this debilitated population. A
recent report assessing Quality of Life-Class ranking in 57
patients with ESRD undergoing IBG noted significantly
lower scores at both 30 days and 1 year than in NL
patients undergoing IBG.23 This series indicated that only
21% of patients with ESRD who underwent IBG were
ambulating at 1 year, with a disturbing reduction to 7%
walking independently at 2 years.22 Further studies are
urgently needed to examine the functional consequences
of surgical intervention for limb salvage in this cohort,
including a critical comparative assessment of the conse-
quences of primary amputation. 
CONCLUSION
Our current experience supports aggressive treatment
of limb-threatening ischemia in selected patients with
ESRD. Perioperative mortality and morbidity and long-
term graft function are similar to patients undergoing IBG
with NL. Limb loss, despite a patent graft, occurs with
higher frequency in this group. Currently, the only sug-
gestive preoperative predictor of hemodynamic failure that
we have identified is extensive tissue necrosis of the heel
(wet gangrene or soft eschar > 4 cm). Adjunctive wound
healing strategies such as free tissue transfer, vacuum
devices, or topical growth factor therapies merit further
investigation in an effort to augment limb salvage in this
difficult population.
We acknowledge the assistance of Ms Julie Lombarra
for maintenance of the vascular registry, retrieval of data,
and statistical analysis.
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Dr Daniel B. Walsh (Lebanon, NH). We continue to admire
and be challenged by the excellent results that the group at the
Brigham can achieve. In a review of our own pedal branch artery
bypass population, we found that our results in patients who were
dialysis dependent were actually better than the results of patients
who were not. I point that out just because of our own concern.
I think that is true because our bias is still that patients in dialy-
sis-dependent renal failure have worse results and therefore, we
will only attempt limb salvage in those patients in whom every
condition is optimal: the best vein, the best skin, the best sort of
everything. Despite the fact that we too have achieved what we
think are surprisingly good results in patients with dialysis depen-
dence, we worry that we have a selection bias, and I wonder if you
thought about that as you were retrospectively reviewing how
these patients were chosen for operation and who were not.
Dr John C. Lantis II. Thank you very much, Dr Walsh.
Selection bias in any retrospective study is a major concern. Our
group discussed the possibility that we were selecting “better”
patients for distal bypass within the end-state renal disease group
than the other groups. Unfortunately, we were unable to ade-
quately answer this question. In this retrospective analysis, we
were not able to identify all patients who presented for evaluation
in any of the groups. Therefore, we don’t have a profile of those
patients who were treated nonoperatively. On the other hand,
some of the technical variables were more favorable in the ESRD
group. In the ESRD population 94% of the bypasses were pri-
mary, compared with the other groups where 22% to 24% of the
bypasses were reoperative cases. There were significantly fewer
composite vein grafts in the ESRD patients. These differences
may speak to some selection bias or the fact that we still do very
little reoperative work for what we perceive to be this very high-
risk population. However, without a detailed assessment of all
patients seen for symptomatic peripheral vascular disease, we can-
not fully comment on the presence or lack of bias.
Dr Jeffrey Kaufman (Springfield, Mass). I like those
angiograms because they show relatively clean arteries without
the triple density sign indicating a lot of calcification. Our patients
must be different in western Massachusetts. The problem of arte-
rial calcification seems to be epidemic these days, especially in the
patient with diabetes and renal failure. What are you doing in this
group? Are there any patients you cannot operate on because of
the calcification in the arteries?
Dr Lantis. Thank you very much for an interesting question.
We did not choose a particular way of assessing the level of calci-
nosis or density of the vessel wall. In addition, we did not specif-
ically assess issues such as secondary hyperparathyroidism. As to
what we are doing in this group, we have stuck to fundamental
principles of using the best inflow site and the best outflow site as
accommodated by the length of good conduit available. In gen-
eral we try to avoid extensive distal endarterectomies, but they are
used in some cases to facilitate anastomosis. Recently, we have
used intraoperative duplex ultrasound fairly routinely in all lower
extremity reconstructions. This helps to identify disrupted
plaques at the anastomoses. I am not aware of any patients who
were turned down for bypass or aborted surgery because of calci-
fication of the arteries.
Dr David Brewster (Boston, Mass). John, what about use of
tourniquets for control? We have found this technique quite use-
ful in such patients with highly calcified vessels.
Dr Lantis. This is a very useful technical point. We use tourni-
quets as well, depending mostly on the preference of the operat-
ing surgeon. At times we also use 2F embolectomy balloons for
control or Yasergil clips. Overall, we have found tourniquets for
distal vessel control to be quite helpful.
Dr Frank LoGerfo (Boston, Mass). John, one point I would
emphasize, in patients with renal failure and diabetes: you want to
get as close to the lesion as possible with your bypass graft and
often for us that is a dorsalis pedis artery. In your data you have
one of 20 dorsalis pedis bypass grafts where you had to do an
amputation with a patent graft and you had eight of 54 patent 
tibial bypasses where you had to do an amputation. In our prac-
tice, it would take a really impressive anterior tibial artery to keep
us from going to the dorsalis pedis because of the importance of
getting absolute maximum blood flow to the foot.
Dr Lantis. Thank you for bringing up this point. Members of
our own group have previously presented data showing that per-
oneal bypasses are adequate in order to heal foot wounds. These
results have been in a population with very high diabetes pene-
trance, although without a high occurrence of renal failure. Your
point is well taken that within the group with “hemodynamic fail-
ure” we may have improved the PVR tracings without providing
true “pulsatile flow” to the foot. Because of the observational
nature of the study, it was not always clear as to exact nature of
the pulse or signal in the foot at the completion of the case. Also,
I did not always find the foot angiograms to be of a high quality
or sensitivity. Because of the upstream lesions, sometimes the
quality of the foot angiogram is inadequate to provide for opera-
tive planning. Therefore, in patients with what appear to be very
poor foot vasculature, we have used MRA and ultrasound to facil-
itate planning of distal targets.
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